Form 4: Lyell Immunopharma Director Acquires 130,000 Stock Options
SEC Form 4
Director Otis W. Brawley acquired 130,000 stock options in Lyell Immunopharma, Inc. on May 15, 2025.
Summary
- On May 15, 2025, Otis W. Brawley, a director of Lyell Immunopharma, Inc., acquired 130,000 options to purchase common stock.
- The exercise price of these options is $0.4017.
- The options vest on the earlier of the next annual meeting of stockholders following May 15, 2025, or the first anniversary of May 15, 2025, contingent upon continuous service.
- The options expire on May 14, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of stock options, which can be seen as a positive sign of confidence but doesn't inherently indicate significant positive or negative news.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the options is contingent upon the director's continuous service, suggesting an incentive for continued involvement with the company.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Comparison to Industry Standards
- Stock option grants are a common component of compensation packages for directors and executives in the biotechnology industry, similar to companies like Gilead Sciences, Amgen, and Regeneron.
- The vesting schedule and exercise price are typical for such grants, aligning with industry practices to incentivize long-term value creation.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of earliest transaction: Director acquired 130,000 stock options with an exercise price of $0.4017. |
| 05/15/2025 | Vesting date: Options vest on the earlier of the next annual meeting of stockholders following this date or the first anniversary of this date, subject to continuous service. |
| 05/14/2035 | Expiration date: Options expire on this date. |
| 05/19/2025 | Date of signature of the report. |
Keywords
Lyell Immunopharma, Director, Stock Options, Beneficial Ownership, Form 4, LYEL, Brawley
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.